Inari Medical’s (NASDAQ:NARI) quiet period will end on Wednesday, July 1st. Inari Medical had issued 8,202,565 shares in its public offering on May 22nd. The total size of the offering was $155,848,735 based on an initial share price of $19.00. During Inari Medical’s quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
A number of equities research analysts have weighed in on NARI shares. Bank of America started coverage on shares of Inari Medical in a research note on Tuesday, June 16th. They set a “neutral” rating and a $56.00 price target on the stock. Wells Fargo & Co started coverage on shares of Inari Medical in a research note on Tuesday, June 16th. They set an “equal weight” rating and a $49.00 price target on the stock. Canaccord Genuity assumed coverage on shares of Inari Medical in a research note on Friday, June 19th. They set a “buy” rating and a $60.00 price target on the stock. Finally, Morgan Stanley assumed coverage on Inari Medical in a report on Tuesday, June 16th. They set an “equal weight” rating and a $52.00 price objective for the company.
Shares of NASDAQ NARI opened at $48.02 on Wednesday. Inari Medical has a 52-week low of $39.55 and a 52-week high of $54.86.
Inari Medical Company Profile
There is no company description available for Inari Medical Inc
Further Reading: How does a dividend reinvestment plan work?
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.